<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4004">
  <stage>Registered</stage>
  <submitdate>25/06/2013</submitdate>
  <approvaldate>25/06/2013</approvaldate>
  <nctid>NCT01896986</nctid>
  <trial_identification>
    <studytitle>HPV Vaccination in Special Risk Groups: 5 Year Follow-up</studytitle>
    <scientifictitle>HPV Immunisation Protecting Special Risk Group Patients From Cervical Cancer: 5 Year Follow-up Post-vaccination</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HPV girls 5year followup</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>PRD (Paediatric Rheumatological Disease)</healthcondition>
    <healthcondition>IBD (Inflammatory Bowel Disease)</healthcondition>
  </conditions>
  <interventions>
    <interventions>PRD patrients - Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)
Subgroups:
receiving immunosuppressant therapy
not on immunosuppressant therapy

IBD patients - Children/adolescent females 12-26 years diagnosed with IBD.
Subgroups:
3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Immunogenicity to HPV Vaccine Gardasil - To evaluate the long term immunogenicity of the quadrivalent 4/6/11/18 HPV vaccine GardasilÂ® by following up a cohort of adolescent females aged 16-30 years with PRD or IBD, 5 years post HPV vaccination at the Royal Children's Hospital (RCH) Melbourne .</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Females who participated in the initial HPV vaccine immunogenicity study in 2007.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>26</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inability to provide informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>37</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Childrens Hospital - Melbourne</hospital>
    <postcode>2106 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Murdoch Childrens Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash Medical Centre</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In 2007-2009 the investigators conducted a study to determine the immunogenicity response to
      HPV vaccine in special risk patients known to be at increased risk of abnormal cervical
      cytology. The serological response to the vaccine was measured 1 month post the third and
      final dose (n=70) finding a robust response overall.

      The aim of this follow-on study is to provide data on the long-term protection offered by the
      HPV vaccination. The persistence of antibody 5 years post immunisation is unknown and the
      impact on cervical cytology abnormalities in these special risk groups is important.

      The study results will help inform national immunisation program recommendations re- booster
      HPV vaccine doses.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01896986</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nigel Crawford, PhDMPHMBBS</name>
      <address>Royal Childrens Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>